UOHUniversity of Oklahoma-Health Sciences Center · Biology
RET Inhibition and Drug Resistance Unit
Jie Wu · Oklahoma City, Oklahoma
Research Focus
Jie Wu's lab at the University of Oklahoma focuses on developing new drugs that target the RET oncogene in cancers such as lung and thyroid cancer. The lab aims to create next-generation RET inhibitors that can effectively treat patients who have developed resistance to existing therapies. By optimizing novel compounds, they work towards providing better therapeutic options for patients with RET-positive tumors.
RET inhibitiononcogenecancer therapydrug resistancepharmacokineticsdrug designpreclinical trialsselective kinase inhibitors
Research Aims
4AIM 01Characterize novel nicotinamide-based RET inhibitors to determine their effectiveness.
AIM 02Optimize lead compounds based on their structure-activity relationships.
AIM 03Evaluate pharmacokinetic and toxicity profiles of selected inhibitors.
AIM 04Assess the anti-tumor efficacy of inhibitors in various cancer models.
Skills the Lab Values
cell culturedrug formulationanimal models (mice)in vivo imagingpharmacokinetic studiesstructure-activity relationship analysisbiomarker validationdata analysis in drug development
Output against the department
Publications1,619top 1% of dept.5th of 1,033
this lab
most publishedleast published
Citations27ktop 13% of dept.139th of 1,033
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.